Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire

References

• Avrameas S. Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol. Today 12(5), 154–159 (1991).
   PubMedGoogle Scholar
• Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr. Opin. Immunol. 7(6), 812–818 (1995).
   PubMed Web of Science ®Google Scholar
• Dighiero G, Lymberi P, Mazie JC et al. Murine hybridomas secreting natural monoclonal antibodies reacting with self antigens. J. Immunol. 131(5), 2267–2272 (1983).
   PubMed Web of Science ®Google Scholar
• Haspel MV, Onodera T, Prabhakar BS, Horita M, Suzuki H, Notkins AL. Virus-induced autoimmunity: monoclonal antibodies that react with endocrine tissues. Science 220(4594), 304–306 (1983).
   PubMed Web of Science ®Google Scholar
• Haspel MV, Onodera T, Prabhakar BS et al. Multiple organ-reactive monoclonal autoantibodies. Nature 304(5921), 73–76 (1983).
   PubMed Web of Science ®Google Scholar
• Prabhakar BS, Saegusa J, Onodera T, Notkins AL. Lymphocytes capable of making monoclonal autoantibodies that react with multiple organs are a common feature of the normal B cell repertoire. J. Immunol. 133(6), 2815–2817 (1984).
   PubMed Web of Science ®Google Scholar
• Satoh J, Prabhakar BS, Haspel MV, Ginsberg-Fellner F, Notkins AL. Human monoclonal autoantibodies that react with multiple endocrine organs. N. Engl. J. Med. 309(4), 217–220 (1983).
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Kaveri SV, Mouthon L et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Methods 216(1–2), 117–137 (1998).
   PubMed Web of Science ®Google Scholar
• Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J. Clin. Invest. 117(3), 712–718 (2007).
   PubMed Web of Science ®Google Scholar
• Avrameas S, Selmi C. Natural autoantibodies in the physiology and pathophysiology of the immune system. J. Autoimmun. 41, 46–49 (2013).
   PubMed Web of Science ®Google Scholar
• Avrameas S, Ternynck T. The natural autoantibodies system: between hypotheses and facts. Mol. Immunol. 30(12), 1133–1142 (1993).
   PubMed Web of Science ®Google Scholar
• Brandlein S, Rauschert N, Rasche L et al. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein. Mol. Cancer Ther. 6(1), 326–333 (2007).
   PubMed Web of Science ®Google Scholar
• Pohle T, Brandlein S, Ruoff N, Muller-Hermelink HK, Vollmers HP. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res, 64(11), 3900–3906 (2004).
   PubMed Web of Science ®Google Scholar
• Rauschert N, Brandlein S, Holzinger E, Hensel F, Muller-Hermelink HK, Vollmers HP. A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab. Invest. 88(4), 375–386 (2008).
   PubMed Web of Science ®Google Scholar
• Vollmers HP, Brandlein S. Natural antibodies and cancer. N. Biotechnol. 25(5), 294–298 (2009).
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Warrington A, Asakura K et al. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 37(3), 241–249 (2002).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Asakura K, Bieber AJ et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl Acad. Sci. USA 97(12), 6820–6825 (2000).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M. A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res. 85(5), 967–976 (2007).
   PubMed Web of Science ®Google Scholar
• Roy B, Shukla S, Lyszkiewicz M et al. Somatic hypermutation in peritoneal B1b cells. Mol. Immunol. 46(8–9), 1613–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Tumas-Brundage KM, Notidis E, Heltemes L, Zhang X, Wysocki LJ, Manser T. Predominance of a novel splenic B cell population in mice expressing a transgene that encodes multireactive antibodies: support for additional heterogeneity of the B cell compartment. Int. Immunol. 13(4), 475–484 (2001).
   PubMed Web of Science ®Google Scholar
• Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26(4), 347–362 (2005).
   PubMed Web of Science ®Google Scholar
• Holodick NE, Tumang JR, Rothstein TL. Immunoglobulin secretion by B1 cells: differential intensity and IRF4-dependence of spontaneous IgM secretion by peritoneal and splenic B1 cells. Eur. J. Immunol. 40(11), 3007–3016 (2010).
   PubMed Web of Science ®Google Scholar
• Kantor AB, Merrill CE, Herzenberg LA, Hillson JL. An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. J. Immunol. 158(3), 1175–1186 (1997).
   PubMed Web of Science ®Google Scholar
• Landsteiner K. The Specificity of Serological Reactions. Harvard University Press, MA, USA (1947).
   Google Scholar
• Casali P, Notkins AL. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol. Today 10(11), 364–368 (1989).
   PubMedGoogle Scholar
• Dighiero G, Guilbert B, Avrameas S. Naturally occurring antibodies against nine common antigens in humans sera. II. High incidence of monoclonal Ig exhibiting antibody activity against actin and tubulin and sharing antibody specificities with natural antibodies. J. Immunol. 128(6), 2788–2792 (1982).
   PubMed Web of Science ®Google Scholar
• Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect. Immun. 65(10), 3997–4004 (1997).
   PubMed Web of Science ®Google Scholar
• Marchalonis JJ, Adelman MK, Robey IF, Schluter SF, Edmundson AB. Exquisite specificity and peptide epitope recognition promiscuity, properties shared by antibodies from sharks to humans. J. Mol. Recognit. 14(2), 110–121 (2001).
   PubMed Web of Science ®Google Scholar
• Notkins AL. Polyreactivity of antibody molecules. Trends Immunol. 25(4), 174–179 (2004).
   PubMed Web of Science ®Google Scholar
• Crouzier R, Martin T, Pasquali JL. Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors. J. Immunol. 154(9), 4526–4535 (1995).
   PubMed Web of Science ®Google Scholar
• Ditzel HJ, Itoh K, Burton DR. Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J. Immunol. 157(2), 739–749 (1996).
   PubMed Web of Science ®Google Scholar
• Ichiyoshi Y, Casali P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J. Exp. Med. 180(3), 885–895 (1994).
   PubMed Web of Science ®Google Scholar
• Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J. Immunol. 152(12), 5988–5996 (1994).
   PubMed Web of Science ®Google Scholar
• Polymenis M, Stollar BD. Critical binding site amino acids of anti-Z-DNA single chain Fv molecules. Role of heavy and light chain CDR3 and relationship to autoantibody activity. J. Immunol. 152(11), 5318–5329 (1994).
   PubMed Web of Science ®Google Scholar
• Fernandez C, Alarcon-Riquelme ME, Sverremark E. Polyreactive binding of antibodies generated by polyclonal B cell activation. II. Crossreactive and monospecific antibodies can be generated from an identical Ig rearrangement by differential glycosylation. Scand. J. Immunol. 45(3), 240–247 (1997).
   PubMed Web of Science ®Google Scholar
• Leibiger H, Wustner D, Stigler RD, Marx U. Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. Biochem. J. 338 ( Pt 2), 529–538 (1999).
   PubMed Web of Science ®Google Scholar
• Leung SO, Dion AS, Pellegrini MC et al. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. Int. J. Cancer 60(4), 534–538 (1995).
   PubMed Web of Science ®Google Scholar
• Wright A, Tao MH, Kabat EA, Morrison SL. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J. 10(10), 2717–2723 (1991).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Oleszak E, Leibowitz J. Theiler's murine encephalomyelitis: a model of demyelination and persistence of virus. Crit. Rev. Immunol. 7(4), 325–365 (1987).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J. Neuropathol. Exp. Neurol. 46(1), 84–95 (1987).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27(1), 12–17 (1990).
   PubMed Web of Science ®Google Scholar
• Miller DJ, Sanborn KS, Katzmann JA, Rodriguez M. Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J. Neurosci. 14(10), 6230–6238 (1994).
   PubMed Web of Science ®Google Scholar
• Paz Soldan MM, Warrington AE, Bieber AJ et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol. Cell Neurosci. 22(1), 14–24 (2003).
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS, Walsh FS, Nirenberg M. Monoclonal antibody to a plasma membrane antigen of neurons. Proc. Natl Acad. Sci. USA 76(10), 4913–4917 (1979).
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Quarles RH, Brady RO. The monoclonal antibody HNK-1 reacts with a human peripheral nerve ganglioside. Biochem. Biophys. Res. Commun. 122(3), 1206–1211 (1984).
   PubMed Web of Science ®Google Scholar
• Sommer I, Schachner M. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev. Biol. 83(2), 311–327 (1981).
   PubMed Web of Science ®Google Scholar
• Asakura K, Miller DJ, Pease LR, Rodriguez M. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J. Neurosci. 18(19), 7700–7708 (1998).
   PubMed Web of Science ®Google Scholar
• Mitsunaga Y, Ciric B, Van Keulen V et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 16(10), 1325–1327 (2002).
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Ciric B, Pease LR, Van Keulen V, Rodriguez M. A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res. 85(5), 967–976 (2007).
   PubMed Web of Science ®Google Scholar
• Asakura K, Miller DJ, Murray K, Bansal R, Pfeiffer SE, Rodriguez M. Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J. Neurosci. Res. 43(3), 273–281 (1996).
   PubMed Web of Science ®Google Scholar
• Asakura K, Pogulis RJ, Pease LR, Rodriguez M. A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. J. Neuroimmunol. 65(1), 11–19 (1996).
   PubMed Web of Science ®Google Scholar
• Pavelko KD, van Engelen BG, Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 18(7), 2498–2505 (1998).
   PubMed Web of Science ®Google Scholar
• Wittenberg NJ, Im H, Xu X et al. High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance. Anal. Chem. 84(14), 6031–6039 (2012).
   PubMed Web of Science ®Google Scholar
• Dubois C, Manuguerra JC, Hauttecoeur B, Maze J. Monoclonal antibody A2B5, which detects cell surface antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer) and to its 9-O-acetylated derivative. J. Biol. Chem. 265(5), 2797–2803 (1990).
   PubMed Web of Science ®Google Scholar
• Fredman P, Magnani JL, Nirenberg M, Ginsburg V. Monoclonal antibody A2B5 reacts with many gangliosides in neuronal tissue. Arch. Biochem. Biophys. 233(2), 661–666 (1984).
   PubMed Web of Science ®Google Scholar
• Burger D, Perruisseau G, Simon M, Steck AJ. Comparison of the N-linked oligosaccharide structures of the two major human myelin glycoproteins MAG and P0: assessment of the structures bearing the epitope for HNK-1 and human monoclonal immunoglobulin M found in demyelinating neuropathy. J. Neurochem. 58(3), 854–861 (1992).
   PubMed Web of Science ®Google Scholar
• Burger D, Simon M, Perruisseau G, Steck AJ. The epitope(s) recognized by HNK-1 antibody and IgM paraprotein in neuropathy is present on several N-linked oligosaccharide structures on human P0 and myelin-associated glycoprotein. J. Neurochem. 54(5), 1569–1575 (1990).
   PubMed Web of Science ®Google Scholar
• Schachner M. Cell type-specific surface antigens in the mammalian nervous system. J. Neurochem. 39(1), 1–8 (1982).
   PubMed Web of Science ®Google Scholar
• Singh H, Pfeiffer SE. Myelin-associated galactolipids in primary cultures from dissociated fetal rat brain: biosynthesis, accumulation, and cell surface expression. J. Neurochem. 45(5), 1371–1381 (1985).
   PubMed Web of Science ®Google Scholar
• Bansal R, Pfeiffer SE. Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids. Proc. Natl Acad. Sci. USA 86(16), 6181–6185 (1989).
   PubMed Web of Science ®Google Scholar
• Bansal R, Stefansson K, Pfeiffer SE. Proligodendroblast antigen (POA), a developmental antigen expressed by A007/O4-positive oligodendrocyte progenitors prior to the appearance of sulfatide and galactocerebroside. J. Neurochem. 58(6), 2221–2229 (1992).
   PubMed Web of Science ®Google Scholar
• Kirschning E, Jensen K, Dubel S, Rutter G, Hohenberg H, Will H. Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis. J. Neuroimmunol. 99(1), 122–130 (1999).
   PubMed Web of Science ®Google Scholar
• Sakakibara K, Momoi T, Uchida T, Nagai Y. Evidence for association of glycosphingolipid with a colchicine-sensitive microtubule-like cytoskeletal structure of cultured cells. Nature 293(5827), 76–78 (1981).
   PubMed Web of Science ®Google Scholar
• Zalc B, Monge M, Dupouey P, Hauw JJ, Baumann NA. Immunohistochemical localization of galactosyl and sulfogalactosyl ceramide in the brain of the 30-day-old mouse. Brain Res. 211(2), 341–354 (1981).
   PubMed Web of Science ®Google Scholar
• Inoko E, Nishiura Y, Tanaka H et al. Developmental stage-dependent expression of an alpha2,8-trisialic acid unit on glycoproteins in mouse brain. Glycobiology 20(7), 916–928 (2010).
   PubMed Web of Science ®Google Scholar
• Dubois C, Magnani JL, Grunwald GB et al. Monoclonal antibody 18B8, which detects synapse-associated antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer). J. Biol. Chem. 261(8), 3826–3830 (1986).
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Hirota M, Matsumoto M, Tanaka H, Obata K, Ando S. Developmental changes of C-series polysialogangliosides in chick brains revealed by mouse monoclonal antibodies M6704 and M7103 with different epitope specificities. J. Biochem. 104(6), 973–979 (1988).
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Hirota M, Suzuki Y, Matsumoto M, Obata K, Ando S. Developmentally expressed O-acetyl ganglioside GT3 in fetal rat cerebral cortex. Neurosci. Lett. 106(1–2), 193–198 (1989).
   PubMed Web of Science ®Google Scholar
• Rosner H, Greis C, Henke-Fahle S. Developmental expression in embryonic rat and chicken brain of a polysialoganglioside-antigen reacting with the monoclonal antibody Q 211. Brain Res. 470(2), 161–171 (1988).
   PubMed Web of Science ®Google Scholar
• Rosner H, Sonnentag U, Meiri K. Developmental changes of growth cone gangliosides of the postnatal rat cerebrum. Neuroreport 4(10), 1207–1210 (1993).
   PubMed Web of Science ®Google Scholar
• Heffer-Lauc M, Cacic M, Serman D. C-series polysialogangliosides are expressed on stellate neurons of adult human cerebellum. Glycoconj. J. 15(4), 423–426 (1998).
   PubMed Web of Science ®Google Scholar
• Carroll WM, Jennings AR. Early recruitment of oligodendrocyte precursors in CNS demyelination. Brain 117 ( Pt 3), 563–578 (1994).
   PubMed Web of Science ®Google Scholar
• Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 19(1), 197–203 (1997).
   PubMed Web of Science ®Google Scholar
• Horner PJ, Power AE, Kempermann G et al. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J. Neurosci. 20(6), 2218–2228 (2000).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Toyama Y, Nishiyama A. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating lesion. J. Neurosci. Res. 69(6), 826–836 (2002).
   PubMed Web of Science ®Google Scholar
• Windrem MS, Roy NS, Wang J et al. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. J. Neurosci. Res. 69(6), 966–975 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang SC, Ge B, Duncan ID. Adult brain retains the potential to generate oligodendroglial progenitors with extensive myelination capacity. Proc. Natl Acad. Sci. USA 96(7), 4089–4094 (1999).
   PubMed Web of Science ®Google Scholar
• Watzlawik JO, Warrington AE, Rodriguez M. PDGF is required for remyelination-promoting igm stimulation of oligodendrocyte progenitor cell proliferation. PLoS ONE 8(2), e55149 (2013).
   PubMed Web of Science ®Google Scholar
• Kleine TO, Hackler R, Zofel P. Age-related alterations of the blood-brain-barrier (bbb) permeability to protein molecules of different size. Z. Gerontol. 26(4), 256–259 (1993).
   PubMed Web of Science ®Google Scholar
• Argaw AT, Asp L, Zhang J et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122(7), 2454–2468 (2012).
   PubMed Web of Science ®Google Scholar
• Pirko I, Ciric B, Gamez J et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 18(13), 1577–1579 (2004).
   PubMed Web of Science ®Google Scholar
• Broman T. Blood-Brain Barrier Damage in Multiple Sclerosis Supravital Test-Observations. Acta Neurol. Scand. Suppl. 40, ( Suppl. 10), 21–14 (1964).
   Google Scholar
• McQuaid S, Cunnea P, McMahon J, Fitzgerald U. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis. Biochem. Soc. Trans. 37( Pt 1), 329–331 (2009).
   PubMed Web of Science ®Google Scholar
• Claudio L, Raine CS, Brosnan CF. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol. 90(3), 228–238 (1995).
   PubMed Web of Science ®Google Scholar
• Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 114 ( Pt 1B), 557–572 (1991).
   PubMed Web of Science ®Google Scholar
• Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J. Neuropathol. Exp. Neurol. 53(6), 625–636 (1994).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 43(6), 809–814 (1998).
   PubMed Web of Science ®Google Scholar
• Kermode AG, Thompson AJ, Tofts P et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113 ( Pt 5), 1477–1489 (1990).
   PubMed Web of Science ®Google Scholar
• Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130( Pt 11), 2800–2815 (2007).
   PubMed Web of Science ®Google Scholar
• Sobel RA. The extracellular matrix in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 57(3), 205–217 (1998).
   PubMed Web of Science ®Google Scholar
• Sobel RA, Chen M, Maeda A, Hinojoza JR. Vitronectin and integrin vitronectin receptor localization in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 54(2), 202–213 (1995).
   PubMed Web of Science ®Google Scholar
• Sobel RA, Mitchell ME. Fibronectin in multiple sclerosis lesions. Am. J. Pathol. 135(1), 161–168 (1989).
   PubMed Web of Science ®Google Scholar
• Vos CM, Geurts JJ, Montagne L et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 20(3), 953–960 (2005).
   PubMed Web of Science ®Google Scholar
• Howe CL, Bieber AJ, Warrington AE, Pease LR, Rodriguez M. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol. Dis. 15(1), 120–131 (2004).
   PubMed Web of Science ®Google Scholar
• Kanter JL, Narayana S, Ho PP et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12(1), 138–143 (2006).
   PubMed Web of Science ®Google Scholar
• Mitsunaga Y, Ciric B, Van Keulen V et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. Faseb. J. 16(10), 1325–1327 (2002).
   PubMed Web of Science ®Google Scholar
• Watzlawik J, Holicky E, Edberg DD et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 58(15), 1782–1793 (2010).
   PubMed Web of Science ®Google Scholar
• Bansal R, Winkler S, Bheddah S. Negative regulation of oligodendrocyte differentiation by galactosphingolipids. J. Neurosci. 19(18), 7913–7924 (1999).
   PubMed Web of Science ®Google Scholar
• Ranscht B, Wood PM, Bunge RP. Inhibition of in vitro peripheral myelin formation by monoclonal anti-galactocerebroside. J. Neurosci. 7(9), 2936–2947 (1987).
   PubMed Web of Science ®Google Scholar
• Stangel M, Bernard D. Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination. J. Neuroimmunol. 138(1–2), 25–30 (2003).
   PubMed Web of Science ®Google Scholar
• Pringle N, Collarini EJ, Mosley MJ, Heldin CH, Westermark B, Richardson WD. PDGF A chain homodimers drive proliferation of bipotential (O-2A) glial progenitor cells in the developing rat optic nerve. EMBO J. 8(4), 1049–1056 (1989).
   PubMed Web of Science ®Google Scholar
• Silberstein FC, De Simone R, Levi G, Aloisi F. Cytokine-regulated expression of platelet-derived growth factor gene and protein in cultured human astrocytes. J. Neurochem. 66(4), 1409–1417 (1996).
   PubMed Web of Science ®Google Scholar
• van Heyningen P, Calver AR, Richardson WD. Control of progenitor cell number by mitogen supply and demand. Curr. Biol. 11(4), 232–241 (2001).
   PubMed Web of Science ®Google Scholar
• Colognato H, Baron W, Avellana-Adalid V et al. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat. Cell Biol. 4(11), 833–841 (2002).
   PubMed Web of Science ®Google Scholar
• Frost EE, Buttery PC, Milner R, ffrench-Constant C. Integrins mediate a neuronal survival signal for oligodendrocytes. Curr. Biol. 9(21), 1251–1254 (1999).
   PubMed Web of Science ®Google Scholar
• Baron W, Shattil SJ, ffrench-Constant C. The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins. EMBO J. 21(8), 1957–1966 (2002).
   PubMed Web of Science ®Google Scholar
• Baron W, Colognato H, ffrench-Constant C. Integrin-growth factor interactions as regulators of oligodendroglial development and function. Glia 49(4), 467–479 (2005).
   PubMed Web of Science ®Google Scholar
• Redwine JM, Armstrong RC. In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination. J. Neurobiol. 37(3), 413–428 (1998).
   PubMedGoogle Scholar
• Vana AC, Flint NC, Harwood NE, Le TQ, Fruttiger M, Armstrong RC. Platelet-derived growth factor promotes repair of chronically demyelinated white matter. J. Neuropathol. Exp. Neurol. 66(11), 975–988 (2007).
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Quarles RH, MacIntosh TD et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc. Natl Acad. Sci. U.S.A. 81(4), 1225–1229 (1984).
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Willison HJ, Quarles RH et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann. Neurol. 23(5), 440–447 (1988).
   PubMed Web of Science ®Google Scholar
• Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann. Neurol. 37( Suppl. 1), S32–42 (1995).
   PubMedGoogle Scholar
• Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. Muscle Nerve 22(7), 800–822 (1999).
   PubMed Web of Science ®Google Scholar
• Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125( Pt 12), 2591–2625 (2002).
   PubMed Web of Science ®Google Scholar
• Carpo M, Meucci N, Allaria S et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J. Neurol. Sci. 176(2), 144–150 (2000).
   PubMed Web of Science ®Google Scholar
• Dabby R, Weimer LH, Hays AP, Olarte M, Latov N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 54(7), 1448–1452 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Morbin M, Nobile-Orazio E et al. Antisulfatide polyneuropathy: antibody-mediated complement attack on peripheral myelin. Acta Neuropathol. 96(6), 569–574 (1998).
   PubMed Web of Science ®Google Scholar
• Quattrini A, Corbo M, Dhaliwal SK et al. Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons. J. Neurol. Sci. 112(1–2), 152–159 (1992).
   PubMed Web of Science ®Google Scholar
• Chassande B, Leger JM, Younes-Chennoufi AB et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 21(1), 55–62 (1998).
   PubMed Web of Science ®Google Scholar
• Latov N. Antibodies to glycoconjugates in neuropathy and motor neuron disease. Prog. Brain Res. 101, 295–303 (1994).
   PubMed Web of Science ®Google Scholar
• Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J. Neuroimmunol. 95(1–2), 174–184 (1999).
   PubMed Web of Science ®Google Scholar
• Kaida K, Kusunoki S. [Immune-mediated neuropathy and anti-glycolipid antibodies]. Brain Nerve 65(4), 413–423 (2013).
   PubMedGoogle Scholar
• Gorio A, Vitadello M. Ganglioside prevention of neuronal functional decay. Prog. Brain Res. 71, 203–208 (1987).
   PubMed Web of Science ®Google Scholar
• Ledeen RW. Biology of gangliosides: neuritogenic and neuronotrophic properties. J. Neurosci. Res. 12(2–3), 147–159 (1984).
   PubMed Web of Science ®Google Scholar
• Bradley WG, Badger GJ, Tandan R et al. Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia. Neurology 38(11), 1731–1739 (1988).
   PubMed Web of Science ®Google Scholar
• Horowitz SH. Ganglioside (Cronassial) therapy in diabetic neuropathy. Adv. Exp. Med. Biol. 174, 593–600 (1984).
   PubMedGoogle Scholar
• Ledeen RW, Oderfeld-Nowak B, Brosnan CF, Cervone A. Gangliosides offer partial protection in experimental allergic neuritis. Ann. Neurol. 27 Suppl., S69–S74 (1990).
   Web of Science ®Google Scholar
• Oderfeld-Nowak B, Brosnan C, Cervone A, Oderfeld J, Ledeen RW. Gangliosides improve the outcome of experimental allergic neuritis (EAN). Acta Neurobiol. Exp. (Wars) 50(4–5), 495–504 (1990).
   PubMed Web of Science ®Google Scholar
• Ponzin D, Menegus AM, Kirschner G, Nunzi MG, Fiori MG, Raine CS. Effects of gangliosides on the expression of autoimmune demyelination in the peripheral nervous system. Ann. Neurol. 30(5), 678–685 (1991).
   PubMed Web of Science ®Google Scholar
• Zielasek J, Kolb H. Ganglioside therapy of type I diabetes: enhancement of hyperglycemia in the low dose streptozotocin model. Life Sci. 51(1), 49–52 (1992).
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Li D, Yu RK. Lack of apparent neurological abnormalities in rabbits sensitized by gangliosides. Neurochem. Res. 29(11), 2147–2152 (2004).
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Chen ZW. Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy. J. Neuroimmunol. 188(1–2), 34–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez PH, Villa AM, Sica RE, Nores GA. High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies. J. Neuroimmunol. 128(1–2), 69–76 (2002).
   PubMed Web of Science ®Google Scholar
• Hadden RD, Gregson NA, Gold R, Willison HJ, Hughes RA. Guillain-Barre syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. J. Neuroimmunol. 119(2), 306–316 (2001).
   PubMed Web of Science ®Google Scholar
• Sheikh KA, Zhang G, Gong Y, Schnaar RL, Griffin JW. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann. Neurol. 56(2), 228–239 (2004).
   PubMed Web of Science ®Google Scholar
• Yuki N, Susuki K, Koga M et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc. Natl Acad. Sci. USA 101(31), 11404–11409 (2004).
   PubMed Web of Science ®Google Scholar
• Rojas-Garcia R, Gallardo E, Illa I. Paraproteinemic neuropathies. Presse Med. 42(6 Pt 2), e225–e234 (2013).
   Google Scholar
• Dyck PJ, Low PA, Windebank AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 325(21), 1482–1486 (1991).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123 ( Pt 4), 710–717 (2000).
   PubMed Web of Science ®Google Scholar
• Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch. Neurol. 60(2), 260–264 (2003).
   PubMedGoogle Scholar